Research programme: TGF-beta oligonucleotide nanoparticles - Capsulution Pharma
Alternative Names: TGF-B antisense oligonucleotides - NanoDel; TGF-beta antisense oligonucleotides - NanoDelLatest Information Update: 18 May 2011
Price :
$50 *
At a glance
- Originator NanoDel Technologies
- Developer Capsulution Pharma
- Class Antisense oligonucleotides
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 18 May 2011 No development reported - Preclinical for Brain cancer in Germany (unspecified route)
- 17 Aug 2005 Preclinical trials in Brain cancer in Germany (unspecified route)